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Abstract
Copyright © 2016 Wolters Kluwer Health, Inc. All  rights reserved.OBJECTIVES:: Preoperative
chemotherapy and radiation for localized esophageal cancer produces cure rates near 30%
when combined with surgical resection. Vandetanib, a small molecule receptor tyrosine kinase
inhibitor  of  VEGFR-2,  VEGFR-3,  RET,  and  EGFR,  demonstrated  synergy  with  radiation  and
chemotherapy in preclinical models. We conducted a phase I study to assess the safety and
tolerability of vandetanib when combined with preoperative chemoradiation in patients with
localized esophageal carcinoma who were surgical candidates. METHODS:: Patients with stage
II-III esophageal and gastroesophageal junction carcinoma without prior therapy were enrolled in
a 3+3 phase I design. Patients received once-daily vandetanib (planned dosing levels of 100,
200,  and  300  mg)  with  concomitant  daily  radiotherapy  (1.8  Gy/d,  45  Gy  total)  and
chemotherapy, consisting of infusional 5-FU (225 mg/m/d over 96 h, weekly), paclitaxel (50
mg/m, days 1, 8, 15, 22, 29) and carboplatin (AUC of 5, days 1, 29). RESULTS:: A total 9 patients
were enrolled with 8 having either distal esophageal or gastroesophageal junction carcinomas.
All  patients  completed  the  planned  preoperative  chemoradiation  and  underwent
esophagectomy. Nausea (44%) and anorexia (44%) were the most common acute toxicities of
any grade. One grade 4 nonhematologic toxicity was observed (gastrobronchial fistula). One
additional patient suffered a late complication, a fatal aortoenteric hemorrhage, not definitively
related to the investigational regimen. Five (56%) patients achieved a pathologic complete
response. Three (33%) additional patients had only microscopic residual disease. Five (56%)
patients remain alive and disease free with a median follow-up of 3.7 years and median overall
survival of 3.2 years. The maximum tolerated dose was vandetanib 100 mg/d. CONCLUSIONS::
Vandetanib at 100 mg daily is tolerable in combination with preoperative chemotherapy (5-FU,
paclitaxel, carboplatin) and radiation therapy with encouraging efficacy worthy of future study.
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